Investment Community Starts to Weigh in on Solexa. Should 454 Worry? | GenomeWeb

NEW YORK, Feb. 28 (GenomeWeb News) - In recent weeks, investment bank analysts have started to promote Solexa. Pacific Growth Equities has initiated coverage with a 'buy' rating, and Leerink Swann & Company has given the stock an 'outperform' rating.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.